junshi-topalliance-logo.png
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
July 19, 2021 20:41 ET | Junshi Biosciences
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
junshi-topalliance-logo.png
Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
July 01, 2021 21:09 ET | Junshi Biosciences
SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
junshi-topalliance-logo.png
Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014
June 28, 2021 10:22 ET | Junshi Biosciences
SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
junshi-topalliance-logo.png
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
June 03, 2021 20:46 ET | Junshi Biosciences
– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall...
junshi-topalliance-logo.png
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
April 29, 2021 07:30 ET | Junshi Biosciences
SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,...
junshi-topalliance-logo.png
Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
April 22, 2021 08:42 ET | Junshi Biosciences
SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
junshi-topalliance-logo.png
NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma who Failed Platinum-Containing Chemotherapy or Progressed within 12 Months of Neoadjuvant or Adjuvant Platinum-Containing Chemotherapy
April 12, 2021 08:00 ET | Junshi Biosciences
SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
junshi-topalliance-logo.png
Junshi Biosciences Announces Full Year 2020 Financial Results And Provides Corporate Updates
March 30, 2021 10:04 ET | Junshi Biosciences
SHANGHAI, China, March 30, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
junshi-topalliance-logo.png
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
March 03, 2021 06:45 ET | Junshi Biosciences
- BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China and REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd....
junshi-topalliance-logo.png
Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China
February 28, 2021 20:15 ET | Junshi Biosciences
-- Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas-- Junshi will continue to be...